Microvast Q4 Earnings Reinforce Operational Strength but Highlight Persistent Control and Dilution Risks

What happened

Microvast released its Q4 2025 earnings call prepared remarks, detailing financial results amid ongoing scrutiny over internal controls and financing. The company reported revenue growth and gross margins aligning with its raised FY2025 guidance, demonstrating operational execution as it shipped products from a declining backlog. Backlog continued its slide from $350.5 million in March 2025 to $237.7 million by September 2025, signaling demand visibility challenges that could pressure future revenue. Management emphasized remediation of internal control weaknesses, asserting effectiveness as of December 31, 2025, but this follows prior periods of ineffective disclosure controls, requiring sustained proof in upcoming filings. Despite improved liquidity, the capital structure still harbors significant dilution risk from a $125 million ATM facility and over 80 million potential warrant and convertible shares, capping per-share upside.

Implication

The earnings call underscores that Microvast's operational momentum, with strong margins and revenue growth, is real but fragile without backlog stabilization. Internal control remediation is a step forward, but historical inconsistencies mean the next 10-Q must show durable effectiveness to reduce financing friction and support valuation. Backlog erosion raises red flags about future bookings, potentially forcing pricing concessions or slower growth, which could undermine margin retention. Dilution overhang from the ATM and warrants remains a critical headwind, threatening to erase per-share value gains even if operations improve. Therefore, the investment thesis hinges on observable progress in the 2026 Q1 filing, particularly on controls, backlog trends, and ATM usage, reinforcing the need for patience and selective entry points.

Thesis delta

The Q4 earnings call does not shift the core investment thesis; it confirms operational strength but amplifies risks around controls and dilution that keep the WAIT rating intact. Any upside remains contingent on the next 10-Q demonstrating sustained internal control effectiveness and backlog stabilization above $240 million, without accelerated ATM issuance. Thus, the delta is neutral to slightly negative, as progress is incremental and overshadowed by persistent overhangs.